Figure 4
From: Plasma biomarker proteins for detection of human growth hormone administration in athletes
rGH responsive plasma proteins identified and quantified by iTRAQ LC-MS/MS analysis from pooled samples. (A) rGH-treated vs placebo-treated at base line, treatment week 4, treatment week 8, washout at day 1, day 2, day 4, and at 6 weeks after the last rGH injection. (B) rGH treated/treated at baseline at treatment week 4, treatment week 8, washout at day 1, day 2, day 4, and at 6 weeks after the last rGH injection. In both Figs (A and B), (a) two proteins Insulin-like growth factor-binding protein complex acid labile subunit (IGFBP-ALS) and Insulin-like growth factor-binding protein 3 (IBP3) were previously reported by other groups as rGH plasma biomarkers; (b) four novel rGH plasma biomarkers Afamin (AFAM), Apolipoprotein L1 (APOL 1), Extracellular matrix protein 1 (ECM1), and Lumican (LUM) identified by iTRAQ LC-MS/MS analysis in this work.
